Does Rallies show Form 4 insider transactions for RANI?

Yes. Rallies tracks RANI insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is RANI research on Rallies investment advice?

No. Rallies provides research, data, and educational context for RANI. It does not provide personalized investment advice.

RANI (Rani Therapeutics Holdings, Inc. Class A Common Stock) Stock Analysis - Insider Trades

Rani Therapeutics Holdings, Inc. Class A Common Stock (RANI) is a publicly traded Healthcare sector company. As of May 21, 2026, RANI trades at $1.09 with a market cap of $97.14M and a P/E ratio of -3.78. RANI moved +23.81% today. Year to date, RANI is -19.85%; over the trailing twelve months it is +45.51%. Its 52-week range spans $0.39 to $3.87. Analyst consensus is strong buy with an average price target of $7.00. Rallies surfaces RANI's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading RANI stock inside the company?

Recent RANI insider activity includes IMRAN MIR A bought 2.08M, South Cone Investments Limited Partnership sold 4.00M, South Cone Investments Limited Partnership sold 1.92M, McKinley Kate bought 17.96K, and Imran Talat bought 10.30K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

RANI Key Metrics

Key financial metrics for RANI
Metric	Value
Price	$1.09
Market Cap	$97.14M
P/E Ratio	-3.78
EPS	$-0.29
Dividend Yield	0.00%
52-Week High	$3.87
52-Week Low	$0.39
Volume	20.48K
Avg Volume	0
Revenue (TTM)	$3.17M
Net Income	$-36.23M
Gross Margin	0.00%

Recent RANI Insider Trades

IMRAN MIR A bought 2.08M (~$1.26M) on Oct 23, 2025.
South Cone Investments Limited Partnership sold 4.00M (~$11.07M) on Oct 21, 2025.
South Cone Investments Limited Partnership sold 1.92M (~$4.64M) on Oct 20, 2025.
McKinley Kate bought 17.96K (~$29.99K) on Dec 13, 2024.
Imran Talat bought 10.30K (~$19.97K) on Dec 9, 2024.

Latest RANI News

Rani Therapeutics Secures $1.7M Q1 Revenue, Extends Cash Runway to Q4 2027 — May 15, 2026
Rani Therapeutics Lands $1.085B Chugai Deal, Raises $60.3M, Starts Phase 1 RT-114 Trial — Mar 26, 2026

RANI Analyst Consensus

3 analysts cover RANI: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $7.00.

Common questions about RANI

Who is trading RANI stock inside the company?: Recent RANI insider activity includes IMRAN MIR A bought 2.08M, South Cone Investments Limited Partnership sold 4.00M, South Cone Investments Limited Partnership sold 1.92M, McKinley Kate bought 17.96K, and Imran Talat bought 10.30K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for RANI?: Yes. Rallies tracks RANI insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is RANI research on Rallies investment advice?: No. Rallies provides research, data, and educational context for RANI. It does not provide personalized investment advice.